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Abstract
Although the most common mechanism underlying congenital hyperinsulinism is dysfunction of the pancreatic ATP-
sensitive potassium channel, the pathogenesis and genetic origins of this disease remains largely unexplained in more than
half of all patients. UCP2 knockout mice exhibit an hyperinsulinemic hypoglycemia, suggesting an involment of UCP2 in
insulin secretion. However, a possible pathogenic role for UCP2 protein in the development of human congenital
hyperinsulinism or of any human disease has not yet been investigated. We studied ten children exhibiting congenital
hyperinsulinism, without detectable mutations in the known congenital hyperinsulinism-causing genes. Parental-inherited
heterozygous UCP2 variants encoding amino-acid changes were found in two unrelated children with congenital
hyperinsulinism. Functional assays in yeast and in insulin-secreting cells revealed an impaired activity of UCP2 mutants.
Therefore, we report the finding of UCP2 coding variants in human congenital hyperinsulinism, which reveals a role for this
gene in the regulation of insulin secretion and glucose metabolism in humans. Our results show for the first time a direct
association between UCP2 amino acid alteration and human disease and highlight a role for mitochondria in hormone
secretion.
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Introduction
Congenital hyperinsulinism (CHI, OMIM 256450) is a rare
genetic disorder characterised by hyperinsulinemic hypoglycemia
caused by unpredictable excessive insulin secretion. The severity of
the disease varies from a mild form to a severe form which may
require surgical removal of the pancreas to protect the brain from
damage due to recurrent hypoglycemia. Hyperinsulinism may be
caused by a range of biochemical disturbances and molecular
defects. Most severe CHI are due to mutations in both genes
ABCC8 and KCNJ11 encoding ATP-dependent potassium channel
subunits SUR1 and Kir6.2 [1–3]. Other mutations have also been
identified in several other genes [4–9]. However, in approximately
40–50% of all CHI cases, no mutation has been found in any of
these known genes, suggesting the existence of other disease-
associated genes, especially among those sensitive to diazoxide
treatment [10], [11].
The mitochondrial uncoupling protein 2 (UCP2), a member of
the UCP family, is widely expressed in tissues, including pancreatic
islets [12]. Due to the high similarity to UCP1, it has been
proposed that active UCP2 induces regulated leak of protons
across the inner mitochondrial membrane, and as a result,
uncoupled mitochondrial oxidative metabolism from ATP syn-
thesis [13–15]. Consequently, although it is debated, UCP2 is
predicted to reduce the ATP yield from substrate oxidation. Since
in pancreatic b-cells, ATP is a key signal for glucose sensing and
insulin secretion, it was predicted that UCP2 could negatively
regulate glucose-stimulated insulin secretion (GSIS). Overexpres-
sion of UCP2 in isolated rat pancreatic cells decreased ATP
content and inhibited GSIS [16], [17]. Similarly, Ucp2 knockdown
by RNAi in pancreatic beta cells enhanced GSIS [18]. Data
coming from rodents models and animal experiments support the
idea that changes in UCP2 expression and/or activity could
contribute to beta cell dysfunction and to the pathogenesis of
diabetes [19], [20]. Whole-body partial inhibition of UCP2
expression by antisense oligonucleotide treatment reversed hyper-
glycemia in models of diabetes and insulin resistance [21].
Consistent with this, inhibition of UCP2 activity by genipin, a
natural compound from Gardenia, reversed high glucose- and
obesity- induced beta cell function [22]. Also supporting a role for
UCP2 in the regulation of insulin secretion have been studies
performed in Ucp2 knockout mice. These mice have been shown
to exhibit hypoglycaemia as a result of increased GSIS associated
with higher ATP levels in isolated islets [23]. When Ucp2 knockout
mice were crossed with ob/ob mice, the offspring displayed a
significant improvement in glucose tolerance [23]. In addition,
there is also evidence in humans that a functional polymorphism
in the Ucp2 gene promoter correlated with lower insulin secretion
and a higher risk for the development of type 2 diabetes [24–26].
Given that many patients with CHI do not have mutations in
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known CHI-associated genes, and given the implicated role of
UCP2 in the regulation of insulin secretion we investigated UCP2
as a new candidate gene involved in human hyperinsulinic states.
Materials and Methods
Patients and genotype analyses
Written informed consent was obtained from all human
participants before collecting blood for DNA extraction. The
study was approved by Necker-Enfants Malades Hospital review
board. Ten CHI children with no detectable mutations by DNA
direct sequencing in the ABCC8, KCNJ11, GCK or GLUD1 genes
were included in this study. These ten children presenting
repeated hypoglycemias (ranging from 0.9 to 2.3, reference range
.2.7 mmol/l) associated to high insulin levels (ranging from 5.5 to
40 mU/l, reference range ,0.4 in hypoglycemia), consistent with
the diagnosis of congenital hyperinsulinism. Hypoglycaemia
occurred either at birth (5/10 cases) or in infancy (5/10 cases).
Those who underwent surgery (4/10) were subsequently classified
as either diffuse CHI (n = 1) according to previously described
histological criteria [27] or atypical CHI (n = 3), a mosaic of
heterogeneous hyperfunctional islets. The other patients (6/10)
were treated medically with diazoxide. The medical sensitivity to
diazoxide was defined as the complete normalisation of blood
glucose (.3 mmol/l), measured before and after each meal, in
patients fed normally. After that intravenous glucose and other
medications had been stopped for at least five consecutive days.
Resistance to medical treatment was defined as two confirmed
blood glucose measurements lower than 3 mmol/l in a 24-hours
period.
Transhepatic selective pancreatic venous catheterization [28]
was performed to detect diffuse insulin oversecretion in the whole
pancreas or to localize the insulin hypersecretion to a discrete part
of the pancreas. Diazoxide and all other drugs were stopped 7 days
before catheterization. In patients with focal CHI, transhepatic
selective pancreatic venous catheterization typically gave rise to
localised and markedly elevated insulin and C-peptide levels in the
territory of the lesions, with low levels in the remaining pancreas.
Diffuse CHI was considered when increased insulin and C-peptide
levels were found throughout the whole pancreas.
The human UCP2 gene was screened by denaturating high
performance liquid chromatography (DHPLC). Genomic DNA
was purified from peripheral blood leukocytes according to
standard procedures. Primers designed for amplifying UCP2 exons
and exon-intron boundaries are indicated in Table 1. PCR
amplifications consisted of an initial denaturation at 94uC for
5 min, followed by 30 cycles at 94uC for 30 sec, 65uC for 30 sec
and 72uC for 1 min, and a final extension at 72uC for 10 min. The
PCR products were denatured at 95uC for 5 min and allowed to
cool to 25uC for the formation of heteroduplexes. DHPLC was
carried out using a Transgenomic WAVE DHPLC and DNASep
column (TransgenomicTM) as previously described [29] . For
analysis, a flow rate of 0.9 ml/min was used, with the buffer
(0.1 M triethylammonium acetate, 25% acetonitrile) gradient
increased for 3.5 min, as indicated in table 1. PCR products
displaying abnormal DHPLC patterns were purified and directly
sequenced using the PRISMTM Ready Reaction Sequencing Kit
(Perkin-Elmer) on an automatic sequencer (ABI 3100). All
procedures were approved by the review board of the Necker-
Enfants Malades Hospital.
Vector for yeast expression and site-directed
mutagenesis
Wild-type and mutated human UCP2 (hUCP2) cDNA
sequences (as found in patient 1 and patient 2 ) were introduced
into the pYeDP-1/8–10 vector as described previously [30] . Site-
directed mutagenesis was performed using the QuickChange Site-
Directed Mutagenesis Kit according to the manufacturer’s
instructions (Stratagene, La Jolla, California, USA). Sequences of
the synthetic oligonucleotides used were as follows (59 to 39) :
GAAGGGTTCCGaGatCTCTGGAAAGGG(G174D) ;
GAAGGGTTCCGcGaGCgTCTGGAAAGGG(L175V) ;
TTGCTCGTAATGatATcGTCAACTGTGCTGA(A187D) ;
GAAGGAGGGGCCtCGAGgaTTCTACAAAGGGT(A268G).
Plasmids were sequenced to confirm the introduction of
expected mutations by automatic DNA sequencing.
Wild type and mutated human UCP2 cDNA sequences cloned
into the pYeDP-1/8–10 vector were introduced in the diploid
Saccharomyces cerevisiae strain W303 by electroporation. Expression
levels and mitochondrial targeting were analyzed by western blot
Table 1. PCR an DHPLC conditions
Primer Sequence of the primer Melting temperature (uC)
Gradient of acetonitrile
(% tampon B)
Temperature of the
mobile phase (uC)
Pr-exon 1 S
Pr-exon 1 AS
59 agaggaagtgcacttaagac 39
39 gagtacaaacttgggtggga 59
58 Not studied in DHPLC
exon 2 S
exon 2 AS
59 gcatggattgggtgggcttg 39
39 ctggaaagagccacttcactg 59
60 Not studied in DHPLC
exon 3 S
exon 3 AS
59 ttagggaaggtgagtttggg 39
39 tctcgatgctccaaacactg 59
60 52–60 49–57 60 62
exon 4 S
exon 4 AS
59 caaagacacagacccctcaa 39
39 gatcgtggggcctaaaaaac 59
60 56–64 54–62 52–60 59 61 65
exon 5 S
exon 5 AS
59 ggtagaaaatgagtgcaagcc 39
39 tgtaggaggaggaagatcct 59
60 56–64 53–61 61 64
exon 6 S
exon 6 AS
59 gcctctggaaaggtgtgtac 39
39 cttactctccctgcaaaggg 59
62 57–65 49–57 60 62
exon 7 S
exon 7 AS
59 ctggaatgatgggtgaagact 39
39 gctactcacttccaggtggt 59
60 57–65 54–62 60 62
exon 8 S
exon 8 AS
59 ggttggattgaataccaggc 39
39 agaaaaggaaagcatggccc 59
60 57–65 49–57 61 62
doi:10.1371/journal.pone.0003850.t001
Human UCP2 and Insulin
PLoS ONE | www.plosone.org 2 December 2008 | Volume 3 | Issue 12 | e3850
of yeast mitochondrial preparations with polyclonal hUCP2 605
antibody against human UCP2 [31].
Isolation of yeast mitochondria and spheroplasts
Mitochondria were isolated from transformed yeasts grown
overnight in SG medium (2% galactose, 0.67% yeast nitrogen
base, 0.1% casamino acids, 20 mg/L tryptophan and 40 mg/L
adenine) as previously described [30] . Yeast spheroplasts were
also prepared from overnight cultures growing in SG medium
according to Averet et al. [32] .
Proton leak measurements in permeabilized yeast
spheroplasts
Spheroplasts were permeabilized with 0.2 mg/ml nystatin at
30uC in respiration medium containing 1 M sorbitol, 0.5 mM
EGTA, 2 mM MgSO4, 1.7 mM NaCl, 10 mM potassium
phosphate (pH 6.8), 0.1% BSA. Mitochondrial respiration was
measured at 20uC in the presence of 6 mM NADH with an
oxygen electrode. Mitochondrial membrane potential was simul-
taneously determined with a home-made tetraphenylphospho-
nium (TPP+) electrode prepared according to published proce-
dures [33] . The amount of spheroplasts used in the experiments
was adjusted every day to obtain always the same maximal
respiratory rate in the presence of an uncoupler (1 mM FCCP).
The initial state 4 of respiration was obtained in the presence of
10 mg/ml oligomycin . Respiratory chain activity was gradually
inhibited by the addition of increasing concentrations of potassium
cyanide (ranging from 1 to 300 mM).
Adenovirus generation for expression of UCP2 mutants
in insulin-secreting mammalian cells
Recombinant adenoviruses were generated according to the
homologous recombination pAdEasy system as described [34] .
The full-length hUCP2 cDNA as well as the cDNAs carrying
UCP2 mutations equivalent to patient 1 and patient 2 and the rat
UCP1 cDNA were cloned into the shuttle vector pAdTrack-CMV.
This vector allows the production of green fluorescent protein
(GFP)-trackable viruses, as it contains the GFP gene in tandem
with the transgene. Expression of both genes is under control of
different cytomegalovirus promoters. Homologous recombination
between the pAdEasy-1 and pAdTrack-CMV vectors and
production of the wild type (AdhUCP2), mutated hUCP2
(AdhU2Patient1 and AdhU2Patient2) and rUCP1 (AdrUCP1)
adenoviruses were performed at the Laboratoire de The´rapie
Figure 1. Pedigree of Families 1 and 2 with missense heterozygous sequence variations in the UCP2 gene. A. Pedigree: Family 1 (F1):
Patient 1 had neonatal hypoglycaemia, was sensitive to diazoxide and resolved spontaneously at age 1 year. Her parents did not present clinical signs
of hypoglycaemia. Family 2 (F2): Patient 2 developed hypoglycaemia at 8 month of age, sensitive to diazoxide. His mother presented seizures in
infancy and occasional hypoglycaemia. Individuals carrying heterozygous UCP2 sequence variations are indicated by partly closed and partly open
symbols. B. DHPLC patterns (upper part) and corresponding DNA sequences (lower part) of family 1 and family 2.
doi:10.1371/journal.pone.0003850.g001
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Ge´nique (INSERM, Nantes-France). An adenovirus containing
the GFP gene and the inverted sequence of human UCP2
cDNAwas used as control (Adcontrol).
Cell culture and adenoviral infection
The rat insulinoma cell line INS-1E was provided by Dr. P.
Maechler (University of Geneva, Switzerland) [35]. Cells were
seeded in 6-well plates and maintained in RPMI 1640 medium
containing 10% FCS, 10 mM HEPES, 1 mM sodium pyruvate,
50 mM 2-mercaptoethanol, 4 mM glutamine, 100 IU/ml penicil-
lin and 100 mg/ml streptomycin at 37uC under 5% CO2. The cells
were infected at near confluence with Adcontrol, AdhUCP2 and
AdrUCP1 viral stocks at 5.26106 plaque-forming units (pfu)/ml.
To obtain similar amounts of heterologous protein expressed, the
cells were infected with 1.36106 pfu/ml of AdhUCP2Patient1 or
2.66106 pfu/ml of AdhUCP2Patient2 viral stocks. The virus was
applied to cells for 4 h in the absence of serum. The cells were
then washed of virus and supplemented with 10% serum-
containing RPMI 1640 for 48 h.
Mitochondrial isolation from INS-1E cells and western
blot analysis
Cells were washed twice with PBS, scraped and collected by
centrifugation at 2000 g for 5 min at 4uC. Mitochondria were
isolated from cells. 10 mg of mitochondrial proteins were resolved
by SDS-PAGE and transferred to nitrocellulose membranes before
inmunoblotting. UCP2 protein was detected with the anti-hUCP2
(605 batch) [31] or anti-UCP2 (C-20) (Santa Cruz Biotechnology,
Inc, Santa Cruz, CA, USA) antibodies. For UCP1 detection a
polyclonal anti-rat UCP1 antibody prepared in the laboratory was
used. Anti-VDAC/porin antibody (Sigma-Aldrich, St Louis, MO,
USA) was used as loading control of equivalent amount of
mitochondrial proteins.
Assay of insulin secretion
24 h after adenoviral infection, INS-1E cells were cultured
overnight in RPMI 1640 medium containing 5 mM glucose and
10% FCS. Cells were washed and preincubated for 1 h in RPMI
medium without glucose and 1% FCS. The medium was
replaced by 1 ml of Krebs-Ringer bicarbonate buffer (KRBH)
(135 mM NaCl, 3.6 mM KCl, 5 mM NaHCO3, 0.5 mM
NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 mM HEPES
pH 7.4 and 0.1 % fatty acid-free BSA) with 2.5 mM glucose.
When indicated, 32 mM retinoic acid was added to KRBH
medium. After 30 min incubation at 37uC, the cells were
incubated for another 30 min with KRBH containing 15 mM
glucose. When indicated, 32 mM retinoic acid was added to
KRBH medium. The medium was collected and cleared of non
adherent cells. Insulin content in the supernatants was
determined by radioimmunoassay for rat insulin (Linco Re-
search, St. Charles, MO). Total cell protein was determined for
each well with the DC protein assay (Bio-Rad).
Statistical Analysis
Data are presented as means6S.E.M. Results were compared
by Student’s paired t test or one-way ANOVA, where applicable.
The level of significance were indicated as * p,0.01 and **
p,0.001.
Figure 2. Amino acid changes in UCP2 of patients 1 and 2 and conservation among species. Comparison of the aminoacid sequences of
the second moiety of UCP2 from Homo sapiens (GenBank Accession NP003346), Rattus norvegicus (GenBank Accession NP062227), Phodopus
sungorus(GenBank Accession AAG33984), Mus musculus (GenBank Accession NP035801), Canis familiaris (GenBank Accession BAA90457), Sus scrofa
(GenBank Accession NP999454), Cyprinus carpio (GenBank Accession CAB46248), Danio rerio (GenBank Accession NP571251). The multiple sequence
alignment was carried out with Clustal X (v. 1.8) analysis software. The UCP2 consensus sequence was calculated from the site http://coot.embl.de/
cgi/consensus. The ribbon cartoon symbolizes the predicted a-helix domains according to the 3D structure of the ADP/ATP carrier [51]. The putative
transmembrane motifs are marked in grey background and the residues mutated in the two patients in dark grey background. Bold letters in the
upper line represent the aminoacids found in Patient 1 and Patient 2.
doi:10.1371/journal.pone.0003850.g002
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Results
Molecular studies
Details of hypoglycemias and high insulin levels in CHI patients
are given in Materials and Methods section. PCR fragments of
UCP2 exons were synthetized from peripheral blood leukocyte of 10
children with no detectable mutations by DNA direct sequencing in
the ABCC8, KCNJ11, GCK or GLUD1 genes. Each PCR reaction was
subjected to DHPLC analysis and their corresponding elution
profiles were analyzed. Abnormal DHPLC pattern was detected for
2 unrelated patients, born to non-consanguineous parents (Figure 1).
DNA sequence analysis identified respectively 3 and 1 heterozygous
single nucleotide changes in patients 1 and 2, all of them leading to
an amino acid change. Mutations of patient 1 consisted of a G to A
transition at nt 521 changing a conserved glycine into an aspartic
acid (G174D), a C to G transversion at 523 nt changing a conserved
leucine into a valine (L175V) and a C to A transition at nt 560
changing a conserved alanine into an aspartic acid (A187D,
Figure 1). All mutations were inherited from her father. Patient 2
mutation, inherited from her mother, was a C to G transversion at nt
803 changing a conserved alanine into a glycine (A268G, Figure 1).
The amino acid changes identified in these two patients were not
found in 100 control subjects. All these residues are highly conserved
in UCP2 protein from different species (Figure 2). The amino acids
G174 and L175, mutated in patient 1, are localised at the end of the
second matrix loop, just before nucleation of the fourth transmem-
brane a-helix. The residue A187, involved also in the first patient, is
into the fourth transmembrane a-helix. The A268, mutated in the
patient 2, is located at the end of the third matrix hydrophilic loop,
before the sixth transmembrane domain of UCP2 (Figure 2).
Patient 1, a girl, was born at gestational age of 38 weeks (birth
weight 3590 g, length 51.5 cm, head circumference 34 cm) from
two unrelated Caucasian parents. She developed neonatal
hypoglycaemia and was successfully treated by diazoxide during
1 year (data not shown). After this time, diazoxide was stopped
without a recurrence of hypoglycaemia. The parents were healthy.
Patient 2, also a girl, was born at gestational age of 37 weeks
(birth weight 2850 g, birth height 48 cm, head circumference
34 cm) from two unrelated Caucasian parents. She presented with
seizures at 8 months of age which revealed hypoglycaemia.
Clinical and biological investigations confirmed the diagnosis of
hyperinsulinism. Pancreatic venous sampling revealed a diffuse
insulin secretion suggesting a diffuse form of CHI that was
successfully treated by diazoxide for a period of 2 years. The child
was not seen in the department after these two years. Her mother
was found to be occasionally hypoglycaemic at adult age and has
been treated by an antiepileptic drug for seizures during infancy.
Functional studies in yeast
As a measure of respiratory uncoupling, we assessed the proton
conductance of spheroplasts from yeast overexpressing wild type and
the mutated UCP2 proteins carrying the amino acid changes found
in patient 1 and patient 2. Spheroplasts from yeast transformed with
the empty vector were used as control. The results are depicted in
Figure 3. As it has been described previously [12], [36],
overexpression of wild type UCP2 in yeast mitochondria shifted
the curve upward and to the left, which is consistent with an increase
of the proton leak and thus uncoupling of mitochondrial respiration,
compared to the control spheroplasts. Expression of the mutated
forms of UCP2, patient 1 or patient 2, also uncoupled mitochondrial
respiration when compared to control spheroplasts. However, yeasts
expressing patient 1 and patient 2 UCP2 proteins, showed lower
proton permeability compared to the ones expressing wild type
UCP2, suggesting that both mutated proteins were less active than
wild type UCP2. The same results were obtained with isolated
mitochondria (data not shown).
Functional studies in insulin-secreting cells
To assess whether the modification of UCP2 activity observed
in patients 1 and 2 could affect insulin secretion in beta cells, we
subjected an insulin-secreting pancreatic insulinoma cell line (INS-
1E) [35] to adenoviral expression of wild type and mutated UCP2
in mitochondria. Adenovirus expressing rat UCP1 was used as
control of uncoupling protein. The adenovirus concentration was
adjusted for each construct in order to obtain similar amounts of
the UCP2 proteins in the INS-1E cell mitochondria (assessed by
western blot, Figure 4). At the concentrations employed for each
adenoviral construct (see methods section), more than 95% of the
cells were infected and expressed GFP, as evidenced by flow
cytometry and fluorescence microscopy (data not shown). Infection
of INS-1E cells by the recombinant adenoviruses, Ad-hUCP2, Ad-
hU2Patient1and Ad-hU2Patient2, enhanced the mitochondrial
content of the corresponding proteins around 15 times compared
with that of control cells infected with the highest concentration of
adenovirus containing the GFP and the inverted UCP2 cDNA
(Figure 4). Insulin secretion by INS-1E cells expressing UCP1, wild
type and mutant UCP2 proteins was determined in the presence of
15 mM glucose. Results are shown in Figure 5. As expected,
adenoviral UCP2 infection significantly reduced insulin release by
Figure 3. Comparison of the proton leak kinetics of yeast
spheroplasts. Spheroplasts were isolated from control (pYeDP
plasmid, black circles), wild type UCP2 (pYeDP-hUCP2, black triangles)
and mutated (as found in patient 1 and 2) UCP2 (pYeDP-hU2Patient1,
open diamonds and pYeDP-hU2Patient2, grey squares) yeasts as
described in ‘‘Materials and Methods’’ section. Mitochondrial membrane
potential and respiratory rate were simultaneously recorded and varied
by titration with potassium cyanide in the presence of NADH. These
experiments were performed in the presence of oligomycin using the
same amount of respiratory chain for the different types of spheroplasts
as determined from the maximal respiratory rate in the presence of
FCCP (for details see ‘‘Materials and Methods’’ section). Respiratory rate
(y axis) is represented as the percentage from the maximal respiratory
rate (Vmax) in the presence of FCCP. Membrane potential (x axis) is
represented as the percentage from the highest membrane potential in
state 4 of respiration. Results are means6S.E.M. of three independent
experiments performed at least in duplicate.
doi:10.1371/journal.pone.0003850.g003
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INS-1E cells (nearly 40% compared to infection with control
adenovirus). In contrast, infection of INS-1E cells with AdhU2-
Patient 1 or AdhU2Patient 2 did not modify the insulin secretion
levels from control values. Similar results were obtained with cells
overexpressing UCP1. Actually, this was probably due to the high
concentration of cytosolic nucleotides that keeps UCP1 activity
inhibited since a decrease of near 40% of the insulin release was
observed in INS-1E cells overexpressing UCP1, when UCP1
activity was stimulated by 32 mM retinoic acid (Figure 5), a known
activator of UCP1 [36].
Discussion
Although most severe CHI are due to mutations in both genes
ABCC8 and KCNJ11 [1–3], other mutations have also been identified
in the glucokinase gene (GCK) [4], the glutamate dehydrogenase gene
[5], (GLUD1), the short-chain L-3-hydroxyacyl-CoA dehydrogenase
gene (SCHAD) [6], the insulin receptor gene [7], the HNF4A gene in
the setting of maturity-onset diabetes (MODY) [8], and the SLC16A1
gene which encodes monocarboxylate transporter 1 (MCT1) in the
setting of exercise-induced hypoglycaemia [9]. Nevertheless, a large
number of CHI cases remain unexplained. The importance of ATP
level or ATP/ADP ratio in the control of insulin secretion indicates
that mitochondria and oxidative metabolism may play an important
role in this event. Interestingly, UCP2, which encodes a mitochon-
drial transporter, was initially presented as a gene possibly linked to
obesity and hyperinsulinism in mice since it maps to regions of
human chromosome 11 and mouse chromosome 7 that have been
linked to hyperinsulinemia and obesity [12].
In agreement with an expected role for UCP2 in the regulation
of insulin secretion, its ability to inhibit insulin secretion in
animals, although it was questionned [37], was largely document-
ed both using experimental modulations of UCP2 level [15–18],
[21] or activity [22] in insulin-secreting cells and analysis of
Ucp2-null mice [23]. In addition, other animal studies suggested
that UCP2-mediated control of insulin secretion is a physiologi-
cally-relevant mechanism of the metabolic response to fasting since
UCP2 has been proposed to keep insulin secretion low during
starvation [38], [39], this function being under the control of the
transcription co-repressor, surtuin-1 [40], [41]. UCP2 negatively
Figure 4. Expression levels of wild type, mutated UCP2 and UCP1 in mitochondrial extracts isolated from insulinoma INS-1E cells
after adenoviral infection. Gels were loaded with 10 mg of mitochondrial proteins and analyzed by Western blot. A) INS-1E cells were infected
with control adenovirus (Adcontrol, containing the GFP gene and the inverted sequence of human UCP2 cDNA at 5.26106 plaque-forming units
(pfu)/ml) or with wild type (AdhUCP2 at 5.26106 pfu/ml) or mutated (AdhU2Patient1 at 1.36106 pfu/ml and AdhU2Patient2 at 2.66106 pfu/ml) UCP2
adenovirus. Mitochondria-rich fraction from not infected INS-1E cells was also used as control of endogenous UCP2 expression. 1 mg of mitochondrial
proteins from yeasts overexpressing human UCP2 (pYeDP-hUCP2) were used as positive control. UCP2 protein was revealed using anti-hUCP2
antibody [31] and anti-UCP2 (C-20) (Santa Cruz Biotechnology, Inc, Santa Cruz, CA). As a control of similar amount of proteins loaded, the membrane
was reprobed with anti-VDAC/Porin antibody (Sigma-Aldrich, St Louis, MO, USA). B) INS-1E cells were infected with control (Adcontrol, containing the
GFP gene and the inverted sequence of human UCP2 cDNA) or with rat UCP1 adenovirus (AdrUCP1) both at a concentration of 5.26106 pfu/ml.
Mitochondria-rich fraction from not infected INS-1E cells was also used as control of endogenous expression. 40 ng of purified rat UCP1 were used as
positive control. UCP1 protein was revealed using a polyclonal anti-rat UCP1 antibody prepared in the laboratory. As a control of similar amount of
proteins loaded, the membrane was reprobed with anti-VDAC/Porin antibody (Sigma-Aldrich, St Louis, MO, USA).
doi:10.1371/journal.pone.0003850.g004
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regulates glucose sensing in hypothalamic neurons and participates
to metabolic switch from glucose metabolism to fatty acid
oxidation during starvation [42], [43]. In addition to a possible
role as a regulator of ATP level, it has also been proposed that
UCP2 could either act through a modulation of ROS levels by
mitochondrial activity [15], [44], [45], or through a regulation of
mitochondrial Ca2+ uptake [46]. Undoubtedly, there is still an
uncertainty regarding the mechanism explaining the activity of
UCP2 and other novel UCPs [47] and in the present study we did
not investigate the precise mechanism allowing UCP2 to inhibit
insulin secretion. This question will require further studies.
Despite many animal studies, no report of a role for UCP2 in
insulin secretion in humans was described. The data obtained in
mice prompted us to look for UCP2 mutations in patients
presenting abnormal insulin secretion. The familial pattern of
moderate hyperinsulinism noted in the present study, with more
severe phenotype in children than in the carrier parent,
suggested an autosomal dominant inheritance with variable
expressivity and/or incomplete penetrance. However, it is
important to keep in mind that within moderate forms of
hyperinsulinism, hypoglycemia can be undiagnosed. Similar
intrafamiliar variability was also reported in dominant forms of
hyperinsulinism related to other genes such as SUR1 [48], [49],
GCK [4] and GLUD1 [5]. As far as UCP2 is concerned, age-
depending genetic and environmental factors may be involved in
its regulation. According with this, it has been shown in mice,
that Ucp2 expression increased after birth and decreased later
on in the life [50]. In addition, as newborns and infants have
a higher nutritional intake (in g/kg body weight and day)
than adults, and as glucose and fatty acids increased the
Ucp2 transcription [19], UCP2 dysfunction may have higher
physiopathological implications in children than in adults.
The two procedures used to assay the activity of theUCP2mutants,
expression in yeast or expression in insulinoma cells, were previously
used by us and others [12], [16], [18], [36]. Taken together, these data
show that the mutations identified from 2 CHI patients are associated
with a loss-of-function of the UCP2 protein corresponding to a loss of
uncoupling activity seen in yeast. As a result, whereas the wild type
UCP2 inhibits insulin secretion by pancreatic beta cells, the mutated
UCP2 promote insulin secretion and as such can explain the
hyperinsulinism observed in these patients.
This is the first time that a role for UCP2 in insulin secretion is
shown to be relevant in human disease. These novel findings may
contribute to define the pathogenesis and genetic origins of
congenital hyperinsulinism which remains largely unexplained in
more than half of all patients, and could have wider implications for
unexplained hypoglycaemia and impaired glucose sensitivity. These
data demonstrate that UCP2 should be added to the growing list of
genes in which mutations can lead to CHI, and introduce UCP2 as a
new player in the control of insulin secretion and glucose sensing by
ß-cells in humans. In addition, these results also reinforce the critical
role played by mitochondria in the control of insulin secretion.
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Figure 5. Effect of UCP2 mutations on insulin secretion of INS-1E cells in response to glucose. Insulin release by INS-1E cells expressing
adenoviral wild type (AdhUCP2), mutated (AdhU2Patient1 and AdhU2Patient2) UCP2 or rat UCP1 (AdrUCP1) compared to control (Adcontrol,
containing the GFP gene and the inverted sequence of human UCP2 cDNA). Values represent insulin secreted into the medium as percentage from
the insulin secreted by cells infected with control adenovirus (Adcontrol) in the presence of 15 mM glucose (for details see ‘‘Materials and Methods’’
section). 32 mM retinoic acid (RA) was added to the cultures of AdUCP1 infected cells to activate UCP1 [36]. Data are means6S.E.M. of at least 6
independent experiments performed in duplicate. The level of statistical significance of the differences between cells infected with control
adenovirus and with UCP2 or UCP1 adenovirus is indicated: ** p,0.001 (t test).
doi:10.1371/journal.pone.0003850.g005
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